Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced that its subsidiary, Shanghai Regenelead Therapies Co., Ltd., has conducted the first surgical dosing in a clinical study for its dual adeno-associated virus (AAV) gene therapy, RGL-193, aimed at treating Parkinson’s disease (PD). The procedure took place at the First Affiliated Hospital of University of Science and Technology of China.
During the surgery, advanced medical techniques such as brain stereotactic technology and convection enhanced drug delivery technology were employed to successfully administer the RGL-193 injection to a precise target area within the patient’s brain tissue. The patient has since recovered well from the surgery and has been safely discharged. RGL-193, which is positioned as the first dual AAV gene therapy for PD patients in China, is engineered to enhance the conversion efficiency of levodopa and to protect and repair impaired dopaminergic neurons. This innovative treatment is expected to slow the progression of the disease and reduce the patients’ reliance on oral anti-PD medications.- Flcube.com
